Analysis Tools
immune system
| N |
• myeloid cell function in vitro is normal
|
|
• osteoclast precursors treated in vitro with Tnsfsl1 and macrophage colony stimulating factor exhibit defective osteoclast differentiation compared to similarly treated wild-type cells
• however, markers of mature osteoclast are present and large doses of macrophage colony stimulating factor or coculture with wild-type osteoblasts can partially restore differentiation
|
|
• in vitro, T cell proliferation response to immunization with MOG is 50% less than in similarly treated heterozygous cells used as a control
|
|
• in the skin
|
|
• NK cells exposed to Ly49D antibody exhibit decreased lytic activity towards FcR+ cells compared to similarly treated heterozygous cells used as a control
• NK cell lysis of CHO cells is impaired Ly49D receptor-dependent compared to for heterozygous cells used as a control
• however, lytic activity towards tumor cell lines YAC-1, IC-21, J774, RMA/S, AK7 and AK40 is normal
|
|
• NK cells exhibit increased natural lytic activity towards FcR+ target cells compared to heterozygous cells used as a control
|
|
• in vitro, T cells stimulated with MOG do not produce IFN-gamma unlike heterozygous cells used as a control
|
|
• following treatment with MOG, Freund's adjuvant and pertussis toxin, 30% of mice are completely resistant to the development of experimental autoimmune encephalomyelitis and the remaining mice exhibit reduced disease severity compared to similarly treated heterozygotes used as a control
• mice immunized with MOG exhibit reduced accumulation of leukocytes, macrophages and activated microglial cells compared to in similarly treated heterozygotes used as a control
• Background Sensitivity: female mice are somewhat more susceptible to development of experimental autoimmune encephalomyelitis than male mice likely due to the genetic background
|
skeleton
|
• osteoclast precursors treated in vitro with Tnsfsl1 and macrophage colony stimulating factor exhibit defective osteoclast differentiation compared to similarly treated wild-type cells
• however, markers of mature osteoclast are present and large doses of macrophage colony stimulating factor or coculture with wild-type osteoblasts can partially restore differentiation
|
osteopetrosis
(
J:89583
)
|
• osteoclast fail to resorb mineralized matrix in vivo unlike wild-type cells
• treatment of osteoclast precursors with large doses of macrophage colony stimulating factor does not rescue bone resoprtion
• however, coculture of osteoclast precursors with wild-type osteoblasts partially restores osteaoclasts bone resorption
|
hematopoietic system
|
• osteoclast precursors treated in vitro with Tnsfsl1 and macrophage colony stimulating factor exhibit defective osteoclast differentiation compared to similarly treated wild-type cells
• however, markers of mature osteoclast are present and large doses of macrophage colony stimulating factor or coculture with wild-type osteoblasts can partially restore differentiation
|
|
• in vitro, T cell proliferation response to immunization with MOG is 50% less than in similarly treated heterozygous cells used as a control
|
|
• in the skin
|
|
• NK cells exposed to Ly49D antibody exhibit decreased lytic activity towards FcR+ cells compared to similarly treated heterozygous cells used as a control
• NK cell lysis of CHO cells is impaired Ly49D receptor-dependent compared to for heterozygous cells used as a control
• however, lytic activity towards tumor cell lines YAC-1, IC-21, J774, RMA/S, AK7 and AK40 is normal
|
|
• NK cells exhibit increased natural lytic activity towards FcR+ target cells compared to heterozygous cells used as a control
|
cellular
|
• osteoclast precursors treated in vitro with Tnsfsl1 and macrophage colony stimulating factor exhibit defective osteoclast differentiation compared to similarly treated wild-type cells
• however, markers of mature osteoclast are present and large doses of macrophage colony stimulating factor or coculture with wild-type osteoblasts can partially restore differentiation
|
|
• in vitro, T cell proliferation response to immunization with MOG is 50% less than in similarly treated heterozygous cells used as a control
|
